## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Ch	eck this box if no longer subject to
Sec	ction 16. Form 4 or Form 5
obl	igations may continue. See
Ins	truction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person <sup>*</sup> Aryeh Jason			2. Issuer Name and Ticker or Trading Symbol <u>NABI BIOPHARMACEUTICALS</u> [NABI]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				X	Director	10% Owner		
(Last) 34 SUMMER R	(First) D.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/15/2011		Officer (give title below)	Other (specify below)		
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicab Line)				
(Street) GREENWICH	СТ	06831		X	Form filed by One Repor	0		
(City)	(State)	(Zip)			Person			

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	if any '	Code (Ins				3, 4 and	Securities Beneficially	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	03/15/2011		S		<b>4,900</b> <sup>(1)</sup>	D	\$5.87	131,783	Ι	Indirect <sup>(2)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of		6. Date Exerc Expiration Da (Month/Day/Y	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

#### Explanation of Responses:

1. The sale reported in this Form 4 was of shares beneficially owned by Jason Aryeh through JALAA Equities, LP.

2. Consists of shares benefically owned by Jason Aryeh through his relationship with JALAA Equities, LP, the Jason Aryeh Trust, the Jason Aryeh 2003 Family Trust, and the Jason Aryeh IRA (collectively, the "Aryeh Entities"). Mr. Aryeh disclaims beneficial ownership of all securities held through the Aryeh Entities, except to the extent of any indirect pecuniary interest he may have therein.

#### Remarks:

James E. Dawson, as attorney-03/17/2011

<u>in-fact</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.